{"id":"pex168-200-g","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL4802213","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PEX168 is a pegylated exenatide derivative designed to provide extended duration of action compared to immediate-release GLP-1 agonists. It binds to and activates the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion, while simultaneously suppressing glucagon secretion and slowing gastric emptying to improve glycemic control in type 2 diabetes.","oneSentence":"PEX168 is a long-acting GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:45.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02472236","phase":"PHASE1","title":"Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2015-06-08","conditions":"Healthy","enrollment":16},{"nctId":"NCT02447601","phase":"PHASE1","title":"Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2015-03-30","conditions":"Type 2 Diabetes Mellitus","enrollment":16},{"nctId":"NCT02461914","phase":"PHASE1","title":"Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2015-08-01","conditions":"Healthy","enrollment":16},{"nctId":"NCT02477969","phase":"PHASE3","title":"Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2014-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":587},{"nctId":"NCT02477865","phase":"PHASE3","title":"Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2014-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":406},{"nctId":"NCT02467790","phase":"PHASE1","title":"Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2015-02","conditions":"Type 2 Diabetes Mellitus","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Polyethylene Glycol Loxenatide"],"phase":"phase_3","status":"active","brandName":"PEX168(200µg)","genericName":"PEX168(200µg)","companyName":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","companyId":"jiangsu-hansoh-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEX168 is a protein modality, specifically a pegylated form of loxenatide, as indicated by its entry in ChEMBL. PEX168(200µg) is one of the doses being studied in clinical trials, including those for Type 2 Diabetes Mellitus and healthy subjects, as listed on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}